Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort.
Olivier TrédanMaud ToulmondeChristophe Le TourneauLaure MontaneAntoine ItalianoIsabelle L Ray-CoquardChristelle De La FouchardièreFrançois BertucciAnthony GoncalvesCarlos Gomez-RocaBenoit YouValéry AttignonSandrine BoyaultPhilippe A CassierArmelle DufresneSéverine Tabone-EglingerAlain ViariEmilie SohierMaud KamalGwenaël GarinJean Yves BlayDavid PérolPublished in: Cancers (2023)
Sorafenib showed activity in progressive patients with solid tumors harboring somatic genomic alterations in sorafenib-targeted genes. Continuing sorafenib when SD is achieved improves PFR compared to interruption.